|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT01436617 |
|
Date of registration:
|
14/09/2011 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab
IgES |
|
Scientific title:
|
Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab |
|
Date of first enrolment:
|
January 2010 |
|
Target sample size:
|
303 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT01436617 |
|
Study type:
|
Observational |
|
Study design:
|
Time Perspective: Prospective
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
France
| | | | | | | |
|
Contacts
|
|
Name:
|
GERVAIS Radj, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Centre François Baclesse |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Patient informed consent,
- Patient aged over 18 years
- Patients with a WHO performance status = 2,
- Colon cancer or upper aero-digestive tract cytologically or histologically proven
- Patients with an indication to the theoretical use of cetuximab for colon neoplasia
or upper aero-digestive tract,
- Haematological and biochemical compatible with combination therapy with cetuximab.
Exclusion Criteria:
- Patients previously treated with cetuximab,
- A person deprived of liberty or under supervision.
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Allergic Reaction
|
|
Colon Cancer
|
|
Head and Neck Cancer
|
|
Intervention(s)
|
|
Other: blood sample
|
|
Primary Outcome(s)
|
|
Validate the utility of an IgE anti-cetuximab test in the treatment strategy
[Time Frame: 3 years]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|